Harvard AIDS Research, Affiliated Hospitals Hit by Trump Feud
Harvard funnels a portion of its federal grants to research partners, including the Mass General Brigham hospital system, and that money has now largely stopped flowing after the government froze more than $2.6 billion in support. Mass General researchers whose work is affected should 'stop all activity and spending' unless they have found alternative funding, Paul Anderson, the hospital group's chief academic officer, said in a message to staff late last week.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
UnitedHealth Group Incorporated UNH continues to face challenges amid a turbulent healthcare insurance landscape. The passage of the 'One Big Beautiful Bill Act' through Congress, ready for President Donald Trump's signature, threatens to significantly reduce federal Medicaid spending. According to reports, approximately 11.8 million Americans are expected to lose Medicaid coverage by 2034, with 5.2 million affected by new work requirements alone. To curb state-level Medicaid expenditures, the bill gradually limits the use of 'provider taxes' as a revenue source. However, it also allocates $50 billion in funding to support rural hospitals impacted by these cuts. While insurers like UnitedHealth and Humana Inc. HUM may encounter short-term pressure from shrinking Medicaid rolls, they could ultimately benefit as displaced members shift toward private coverage options. UnitedHealth's Medicaid membership declined 4% in 2023, 5.2% in 2024, and 1.4% in the first quarter of 2025. The proposed elimination of ACA marketplace tax credits will likely propel more people into employer-sponsored plans. Meanwhile, Medicare Advantage may gain traction, as seniors grapple with increased out-of-pocket expenses due to rollbacks in Medicare Savings Programs. UnitedHealth's Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025. Another major development shook the market as Centene Corporation CNC, a major Medicaid player, withdrew its 2025 earnings guidance late Tuesday, citing unexpected enrollment shifts and higher medical costs. The move, mirroring UnitedHealth's earlier decision, rattled the managed care sector. Centene shares witnessed massive declines following the news, and peers like UnitedHealth and Humana followed suit. Centene shares plummeted 41.2% following the announcement, dragging down peers: UnitedHealth and Humana dropped 5.4% and 5.1%, respectively, despite broader market gains driven by tech strength and encouraging jobs data. Image Source: Zacks Investment Research From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 12.99, up from the industry average of 11.49. UNH currently carries a Value Score of A. Image Source: Zacks Investment Research The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is pegged at $22.07 per share, implying a 20.2% drop from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
New York Times
42 minutes ago
- New York Times
Beyond the Light Show:The Effects of Fireworks on Animals and People
The rockets, explosions and cascading colors of fireworks are a staple of celebrations throughout the world, whether at the Fourth of July, Diwali or New Year's Eve. But while the clamor of light and sound brings out cheers from revelers, fireworks can cause panic in animals. They also leave behind trails of pollution that take a lingering toll on the environment and people. Here is what to know about the harm fireworks cause and recommendations from experts on how people can celebrate while reducing the impact. A Stress for Animals The intense, erratic sounds and lights from fireworks frighten animals, both wild and domesticated. Fear and stress responses have been documented in pets, zoo animals and wildlife. Wild animals may flee when fireworks start: Weather radars have recorded masses of birds taking flight, and studies have shown fleeing by sea lions and seals. This rush to escape costs the animals energy and can lead to longer-term damage, said Bill Bateman, a professor of ecology at Curtin University in Australia and the author on a review of global research on the impact of fireworks on the environment. The animals may abandon habitats completely, or return with less energy for regular survival. These effects are worse when fireworks occur during migration and breeding seasons. Independence Day in the United States, for example, falls in the breeding season for many coastal birds. Shorebirds are particularly at risk because of their proximity to fireworks and beach crowds, said Nicole Michel, director of quantitative science at the National Audubon Society. Birds frightened by fireworks may abandon their nests, leaving chicks or eggs behind and exposed to threats like predators. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Investors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three years
It is doubtless a positive to see that the OptimizeRx Corporation (NASDAQ:OPRX) share price has gained some 73% in the last three months. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 55% in the last three years. Some might say the recent bounce is to be expected after such a bad drop. While many would remain nervous, there could be further gains if the business can put its best foot forward. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Because OptimizeRx made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over three years, OptimizeRx grew revenue at 16% per year. That's a fairly respectable growth rate. So some shareholders would be frustrated with the compound loss of 16% per year. The market must have had really high expectations to be disappointed with this progress. So this is one stock that might be worth investigating further, or even adding to your watchlist. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts It's good to see that OptimizeRx has rewarded shareholders with a total shareholder return of 34% in the last twelve months. Notably the five-year annualised TSR loss of 1.3% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - OptimizeRx has 1 warning sign we think you should be aware of. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
